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ABSTRACT  
Aim:  Somatoform disorders are common and often chronic. It would be helpful to 
distinguish those patients who are likely to have a positive treatment course from those who 
are likely to follow a negative course. Such studies of different somatoform disorders are 
scarce, especially in secondary psychiatric care. This study examined the 6-month treatment 
course of psychological-, physical symptoms, functioning and its predictors in a naturalistic 
sample of secondary psychiatric care outpatients with somatoform disorders.                                                                                                                      
Method: The present study used Routine Outcome Monitoring (ROM) data of patients 
with somatoform disorders regarding their 6-month treatment course of psychological- and 
physical symptoms as well as functioning. The following patient groups were included: total 
group of somatoform disorders (N=435), and Undifferentiated Somatoform Disorder 
(N=242), Pain disorder (N=102), Body Dysmorphic Disorder (N=51), Hypochondriasis 
(N=40). Measures were: MINI (Mini-International Neuropsychiatric Interview Plus), BSI 
(Brief Symptom Inventory), MADRS (Montgomery-Ǻsberg Depression Rating Scale), BAS 
(Brief Anxiety Scale), SF-36 (Short Form Health Survey 36), and PSC (Physical Symptom 
Checklist).                                                                                                                                                       
Results: The study population generally showed high comorbidity, especially with 
anxiety- and mood disorders. The PSC total score, Body Dysmorphic Disorder, and 
Hypochondriasis were significant predictors for the treatment course of symptoms (BSI), 
while the PSC total score was the only significant predictor for the course of functioning (SF-
36). 
 Conclusion: Secondary psychiatric care outpatients with somatoform disorders showed 
high comorbidity with anxiety- and mood disorders, and an unfavourable 6-month course of 
both symptoms and functioning. Clinical implications are discussed, such as additional 
treatment of comorbidity in somatoform disorders.  
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body dysmorphic disorder, hypochondriasis  
 
 
Key Practitioner Message (3-5 bullet points) 
 Secondary psychiatric care outpatients with somatoform disorders had high 
comorbidity, especially with anxiety- and mood disorders.  
 Additional treatment of this comorbidity is highly recommended. 
 Patients with somatoform disorders also showed unfavourable six-month treatment 
outcome regarding both symptoms and functioning.  
 The PSC total score, Body Dysmorphic Disorder, and Hypochondriasis were 
significant predictors for the course of symptoms, while the PSC total score was a 
significant predictor for the course of functioning.  
 
 
1. INTRODUCTION 
 
Individuals with somatoform disorders have physical symptoms for which no somatic cause 
is found. They experience real physical complaints, which are not consciously or deliberately 
imitated (DSM-IV; APA, 2000). Previous studies in somatoform disorders have found high 
comorbidity for anxiety and/or depression, which may increase the likelihood of patients 
holding psychological attributions (Rief et al., 2004; Frostholm et al., 2015). Diagnosis of 
somatoform disorders does not apply when the physical complaints can be explained by other 
psychiatric conditions or by the direct effect of a substance. In some cases, somatoform 
disorders are better understood as a maladaptive response to the physical symptoms, with or 
without a diagnosed somatic disease. This alternative understanding is reflected in the current 
DSM-5 (APA, 2013), where the term “somatoform disorders” has changed in “somatic 
symptom and related disorders”.  
 
Somatoform disorders are quite common, with an estimated prevalence of approximately 6% 
in the general population, 16% in primary care, and up to 52% in secondary care (van Hemert 
et al., 1993; Fink et al., 2004; de Waal et al., 2004; Baumeister & Härter, 2007; Wittchen et 
al., 2010; Creed et al., 2011; Steinbrecher et al., 2011; Houtveen et al., 2015a). Some authors 
assume an even higher prevalence for somatoform disorders as a result of changes in the 
DSM-5 in relation to the diagnostic threshold (Voigt et al., 2013). In secondary mental health 
care, somatoform disorders tend to be persistent and chronic, difficult to treat, and with high 
functional impairment (Dirkzwager & Verhaak, 2007; Steinbrecher & Hiller, 2011; Koelen et 
al., 2014; Houtveen et al., 2015a), resulting in high health care use, and high societal and 
economic costs (Sammet et al., 2007; Konnopka et al., 2012; Houtveen et al., 2015a).  
Research on the natural course of somatoform disorders in non-clinical populations showed 
fluctuation in the symptom picture (Lieb et al., 2002; Essau, 2007; Leikness et al., 2008). 
Medically insufficiently explained physical symptoms may be regarded as a continuum, 
ranging from mild and fleeting to chronic and debilitating symptoms (van Dessel et al., 
2014). This is in line with the concept of “staging”, which suggests that mental disorders may 
have dimensional representations (Ruhé et al., 2012; Wigman et al., 2013). According to the 
model of clinical staging, mental illness is progressing along stages or phases, ranging from 
acute to more chronic (McGorry et al., 2006). Patients with somatoform disorders in the acute 
stage are often treated in primary care by their General Practitioner (GP). In case of persistent 
psychopathology (a more chronic stage), these patients are referred by their GP to secondary 
care for specialised mental health treatment. In general, primary care studies found mixed 
results regarding course of recovery in somatoform disorders (Speckens et al., 1996; Kahn et 
al., 2003; Arnold et al., 2006; Steinbrecher & Hiller, 2011).   
 
Treatment course and its prediction are important aspects of psychopathology that have been 
well characterized in several other psychiatric disorders (Coryell et al., 1996; Yonkers et al., 
2003; Shea et al., 2004; Klein et al., 2008; Eisen et al., 2010, 2013; Hendriks et al., 2013; 
Phillips et al., 2013; Batelaan et al., 2014). Determining appropriate clinical responses based 
upon a likely course of somatoform disorders requires further research, especially in 
secondary mental health care where these course studies are scarce. The few available course 
studies in this area were not, however, focused on the comparison between somatoform 
disorders but on a single somatoform disorder such as Hypochondriasis (e.g. Hiller et al., 
2002) or Body Dysmorphic Disorder  (e.g. Bjornsson et al., 2011; Phillips et al., 2005ab, 
2013). Some possible predictors for treatment course of somatoform disorders were the 
following: physical functioning, functional disability, general health status, 
psychopathological symptoms, attributional style, personality traits, neuroticism, psychiatric 
history, age, gender, negative life events (Hiller et al., 2002; Steinbrecher & Hiller, 2011; 
Zonneveld et al., 2012; van Noorden et al., 2012; Voight et al., 2013; Bergander et al., 2013; 
Pedersen et al., 2016; Weiss et al., 2017). More knowledge on treatment course and its 
predictors in various somatoform disorders would help to distinguish those patients who are 
likely to have a more mild course from those who are likely to follow a severe course 
(McGorry et al., 2006; Gunn et al., 2013). 
The present study examined the 6-month treatment course of different somatoform disorders 
(Undifferentiated Somatoform Disorder, Pain disorder, Body Dysmorphic Disorder, 
Hypochondriasis) in a naturalistic sample of psychiatric outpatients. We used Routine 
Outcome Monitoring (ROM) data of patients who were diagnosed according to the DSM-IV-
R (APA, 2000) at the time of the data collection. As far as we know, this is the first study 
which assessed treatment course of both psychological- and physical symptoms as well as 
functioning for various somatoform disorders in secondary mental health care patients. 
Comparing somatoform disorders with each other could be important to see any differences 
in treatment course. For instance, it seems likely that more complicated somatoform disorders 
(e.g., Body Dysmorphic Disorder, Pain Disorder) show a more negative treatment course 
(Lieb et al., 2002. On the basis of the literature, we expected that patients with Body 
dysmorphic disorder and Pain disorder would exhibit the most negative treatment  course 
(e.g. Lieb et al., 2002). We also expected that number and type of comorbid disorders, age 
and gender would predict a negative treatment course of somatoform disorders (e.g. Kroenke 
et al, 1994). 
 
 
2. METHOD 
2.1 Design 
The treatment course of different somatoform disorders and its predictors were examined 6 
months after baseline (6 months follow-up study; Anstey & Hofer, 2004). The study duration 
had to be limited to 6 months, because there were insufficient data for a longer follow-up.  
 
2.2 Participants and procedure 
The study population consisted of 435 secondary mental healthcare outpatients between 18 
and 65 years with a somatoform disorder as primary diagnosis and possibly additional 
disorders (comorbidity). That is to say, patients of the 4 specific somatoform disorder groups 
(i.e., Undifferentiated Somatoform Disorder, Pain disorder, Body Dysmorphic Disorder, 
Hypochondriasis) had the registered somatoform disorder as primary diagnosis, no other 
somatoform disorder, and possibly a secondary diagnosis of comorbid depression and/or 
anxiety disorder (because somatoform disorder often goes along with this comorbidity; 
Frostholm et al., 2015). Diagnostic information was based on both the Mini-International 
Neuropsychiatric Interview Plus (MINI-Plus, see Measures: having a somatoform disorder) 
and clinical information (patients who were treated for somatoform disorder as primary 
diagnosis). Consequently, patients with primary depression/anxiety disorder and comorbid 
somatoform disorder were excluded. Additionally, three DSM-IV somatoform disorders 
(Somatization disorder, Conversion disorder, Somatoform disorder NOS) were excluded, 
because only a few of these disorders were present in the study population. 
 
Data of participants came from a web-based Routine Outcome Monitoring (ROM) 
programme, in which patients were routinely assessed as part of the standard diagnostic 
procedure (van Noorden et al., 2010, 2012; de Beurs et al., 2011). Patients were referred for 
treatment to  GGZ Rivierduinen Psychiatric Institute (service area of 1.1 million inhabitants). 
Executor of this study was the Department of Psychiatry of the Leiden University Medical 
Centre (LUMC). 
Participants received standard mental health treatment (by psychiatrists and clinical 
psychologists or psychotherapists) according to the principle of stepped-care, based on 
(inter)national evidence-based treatment guidelines, and consisting of pharmacotherapy, 
psychotherapy (mostly CBT) or a combination of both (van Fenema, van der Wee, Giltay, 
den Hollander‐Gijsman, & Zitman, 2012ab; Van Noorden, van Fenema, van der Wee, 
Zitman, & Giltay, 2012). Treatment was not assigned, controlled, or influenced by the 
research team. 
The main objective of ROM is to improve clinical practice by interim monitoring and 
evaluation of treatment progress for the individual patient (Carlier et al., 2012a; 2017; van 
Noorden et al., 2012; Kendrick et al., 2016; Lambert, 2017). ROM measurements (duration 
1-2 hours) can take place before (baseline), during and after treatment. ROM continues for as 
long as the patient is being treated. It consists of an extensive psychometric battery of 
instruments, both self-report and interviewer-based (de Beurs et al., 2011; for an overview of 
instruments see: http://www.lumc.nl/psychiatry/ROM-instruments). The  present study 
focuses on baseline and 6-months assessments, because there were insufficient earlier or  
later data of our study population. All interviewer-based measurements were administered by 
an independent trained assessor (psychiatric research nurse or psychologist). Quality control 
and calibration among assessors ensured quality maintenance during data collection (de 
Beurs et al., 2011). All measurements were completed on touch-screen computers, to prevent 
missing data. Patients with insufficient mastery of the Dutch language were ineligible (van 
Noorden et al., 2012). For more detailed information on the ROM procedure regarding this 
study see: de Beurs et al. (2011); van Noorden et al. (2010, 2012); de Klerk et al. (2011); 
Carlier et al. (2012ab, 2016). 
 
2.3 Measures 
For the purpose of this study, we focused on ROM-data collected with the following 
evidence-based instruments: MINI-Plus, Montgomery-Ǻsberg Depression Rating Scale 
(MADRS), Brief Anxiety Scale (BAS), Brief Symptom Inventory (BSI), Short Form Health 
Survey 36 (SF-36), Physical Symptom Checklist (PSC) (see below).  
 
The choice of these measures was done according to the following criteria: a) besides 
psychopathology also functioning and physical complaints were measured; b) besides patient-
reported measures also clinician-rated instruments were used. In addition, we have used data 
of generic questionnaires only (e.g., BSI for general psychopathology), because they are 
measured in all psychiatric disorders by default in ROM, resulting in the largest possible 
sample size. Consequently, we have not used data of disorder-specific questionnaires, 
because they were only measured in the specific disorder (e.g., BDI-II for depression, as 
indicated by the MINI-Plus), resulting in a much smaller sample size. Related to the focus of 
our study (treatment course), it was obvious to include patients with data on both 
measurement points of baseline and 6 months follow-up. In this context, it turned out that all 
disorder groups in our study had the required data, with the exception of Body dysmorphic 
disorder (BDD, see Table 3) in whom the PSC was not filled in on neither measurement 
moments (because of ROM procedure at the time). It was decided to include BDD without 
PSC-data, because they had all other instruments of this study available at both baseline and 
six-months follow-up.  
Psychiatric diagnoses. DSM-IV diagnoses were assessed using the Dutch translation of the 
Mini-International Neuropsychiatric Interview Plus (MINI-Plus), an extended version of the 
original MINI (Sheehan et al., 1998; Van Vliet & De Beurs, 2007). It is a fully structured 
diagnostic interview that assesses DSM criteria for the main psychiatric disorders 
(current/life-time). The MINI is organized in diagnostic modules. Positive answers to 
screening questions are explored by further investigation of other diagnostic criteria. 
Excellent interrater and test-retest reliabilities of the MINI, and moderate validity of MINI 
versus CIDI and SCID-P have been reported (Lecrubier et al., 1997; Sheehan et al., 1998).  
Psychopathology. Symptoms of psychopathology were measured with the observer rated 
MADRS and BAS (both part of the abbreviated Comprehensive Psychopathological Rating 
Scale, CPRS) and the self-rated BSI. The CPRS is an interviewer-based instrument, and its 
interrater reliability has appeared at least as good as that of the Present State Examination 
(Goekoop et al., 1991). For the present study, the Montgomery-Ǻsberg Depression Rating 
Scale (MADRS; Montgomery and Asberg, 1979) and Brief Anxiety Scale (BAS; Tyrer et al., 
1984) were chosen, because comorbidity of depression and/or anxiety is common in people 
with somatoform disorders. The MADRS and the BAS are observer rated scales used to 
measure the severity of depression and anxiety respectively. Both scales consist of 10 items 
that are scored on a seven point scale, ranging from 0 (none) to 6 (often). The sum of the item 
scores ranges from 0 to 60. Higher scores represent worse depression or anxiety.  
The Brief Symptom Inventory (BSI) is a 53-item self-report instrument that assesses 
psychopathological symptoms in several domains. The BSI is an abbreviated version of the 
Symptom Checklist-90, designed for use in adults in the outpatient medical setting (Derogatis 
et al., 1973). The BSI demonstrates high concordance with clinician symptom assessment and 
strong test–retest and internal consistency reliabilities. It includes nine symptom subscales 
(somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, 
phobic anxiety, paranoid ideation, psychoticism) and a total score. BSI scores range from 0 
(“not-at-all”) to 4 (“extremely”). The subscale and total scores are calculated as an average of 
the relevant items, with higher scores indicating more severe psychopathology (Derogatis et 
al., 1973; Derogatis & Melisaratos, 1983).  
 
Functional health status. The self-report Short Form Health Survey 36 (SF-36), derived from 
the Rand Medical Outcome Study (Aaronson et al., 1998; Ware et al., 1993),  measures 
functional health status and well-being, and can be used as a population-based assessment of 
quality of life. It has demonstrated high levels of reliability and validity (Karlsen et al., 2011). 
The SF-36 consists of 36 items divided into the following subscales: Physical Functioning, 
Social Functioning, Role limitations due to Physical health problems, Role limitations due to 
Emotional problems, Vitality, Bodily Pain, General Mental Health, and General Health 
Perceptions (General Health/total). The latter SF-36 subscale General Health is often 
considered as the total scale for functional health (Ware et al., 1993; Karlsen et al., 2011; 
Pedersen et al., 2016; Wortman et al., 2016; Schröder et al., 2012; Zonneveld et al., 2012). 
Subscale scores are calculated as the sum of the relevant items, ranging from 0 to 100. Lower 
scores correspond to a worse health state (which are inversely scored, so that higher scores 
imply a worse health state; Ware et al., 1993; see also statistical analyses). 
Physical complaints. Participants completed the Physical Symptom Checklist (PSC; de Waal 
et al., 2005). This self-report questionnaire encompasses 55 physical symptoms covering 
most organ systems. The PSC was chosen because it is a self-report questionnaire regarding a 
wide spectrum of possible physical symptoms (not based solely on the DSM but broader than 
that), which are relevant to somatoform disorders but also to other psychiatric disorders. It is 
an evidence-based and license-free instrument (De Waal et al., 2005). The presence of 
symptoms is rated on a severity scale from 0 (none) to 3 (often) for the preceding week. A 
symptom is rated as present for the scores 2 and 3: “bothersome often or most of the time 
during the last week”. Symptoms are grouped in five categories: autonomic (e.g. 
palpitations), general/neurological (e.g. headaches), musculoskeletal/pain (e.g. back pain), 
gastrointestinal (e.g. diarrhea), and warm/cold/urogenital (e.g. hot flushes, difficulty 
urinating) (de Waal et al., 2005).  
 
 
2.4 Statistical analyses  
 
First, all SF-36 subscales were inversely scored, so that higher scores imply a worse health 
state. In addition, all SF-36 subscales are transformed to a 100-points scale (range 0-100; 
Ware et al., 1993). Baseline characteristics of the research groups were compared with Chi-
square test, ANOVA, and Kruskal-Wallis test. There were Post-Hoc comparisons done with 
Bonferroni adjustment to control for multiple testing (see Table 1).. 
 
Second, for treatment course regarding psychological- and physical symptoms (BSI, BAS, 
MADRS, and PSC) and functioning (SF-36), we used paired t-test to compare baseline versus 
6 months (see Tables 2 , 3 and 4).  
 
Third, for the testing of predictors for treatment course, we used the total group of 
somatoform disorders, in order to keep sample size as large as possible. The four somatoform 
disorder groups were used as individual predictors. We used hierarchical multiple regression 
analysis to investigate predictors for the course of symptoms (BSI total, see Table 5) and 
predictors for the course of functioning (SF-36 Physical functioning, based on Zonneveld et 
al., 2012, see Table 6). The course of symptoms was determined by the difference score of 
the BSI total (BSI total at 6 months - BSI total at baseline). The course of functioning was 
determined by the difference score of the SF-36 Physical (SF-36 Physical at 6 months - SF-
36 Physical at baseline; Zonneveld et al., 2012). Predictors were based on the relevant 
literature (e.g., Zonneveld et al., 2012) and their availability in our ROM database.  The 
following control variables were taken into account for the course of symptoms in Table 5 
(e.g., Zonneveld et al., 2012; Iezzoni, 2013; Grant et al., 2014; Ware et al., 1993; Karlsen et 
al., 2011): pretreatment BSI total, age, gender, marital status and employment status. In 
addition, the predictors that were taken into account for the course of symptoms included 
(e.g., Pedersen et al., 2016; Wortman et al., 2016; Schröder et al., 2012; Zonneveld et al., 
2012): education, anxiety disorder, mood disorder, anxiety and mood disorder, total 
diagnoses, PSC total, BAS, MADRS, SF-36 physical functioning, SF-36 social functioning, 
SF-36 general health, and the four somatoform disorder groups (Undifferentiated somatoform 
disorder, Pain disorder, Body dysmorphic disorder, Hypochondriasis). The following control 
variables were taken into account for the course of functioning (Zonneveld et al., 2012): 
pretreatment SF-36 physical functioning, age, gender, marital status, employment status. In 
addition, the predictors that were taken into account for the course of functioning included: 
education, anxiety disorder, mood disorder, anxiety and mood disorder, total diagnoses, PSC 
total, BAS, MADRS, BSI total, and the four somatoform disorder groups (Undifferentiated 
somatoform disorder, Pain disorder, Body dysmorphic disorder, Hypochondriasis).  
 
Statistical analysis was performed using IBM SPSS for Windows version 20.0. Significance 
was reached at p <.01 (e.g., Feise, 2002; Ranstam, 2016). 
 
 
 
2.5 Ethical standards 
 
The Medical Ethical Committee of the LUMC approved the general study protocol regarding 
ROM, in which ROM is considered integral to the treatment process (no written informed 
consent is institutionally required). A comprehensive protocol (titled “Psychiatric Academic 
Registration Leiden database”, www.lumc.nl/psychiatry) was used, which safeguarded the 
anonymity of participants and ensured proper handling of the data. None of the participants 
objected to the anonymized use of their data for scientific purposes. 
 
 
 
 
 
3 RESULTS  
 
3.1 Baseline socio-demographic and clinical characteristics  
 
Table 1 presents the baseline characteristics of the four prevalent somatoform disorders in 
this study: Undifferentiated Somatoform Disorder (n=242), Pain disorder (n=102), Body 
Dysmorphic Disorder (n=51), Hypochondriasis (n=40).  
INSERT TABLE 1 HERE  
 
The groups of somatoform disorders significantly differed in age (F(4,8368)=51.87, p<.001); 
number of comorbid disorders (F(4,8368)=6471.97, p<.001); BSI total (F (5,64)=23.27, 
p<.001); PSC total (F (5,1287)=13.88, p<.001); BAS (F (5,2549)=144.19, p<.001); MADRS 
(F (5,2549)=103.28, p<.001); and SF-36 total (F (5,4568)=97.98, p<.001). Gender 
(X2(4)=48.37, p<.001), marital status (X2(8)=166.63, p<.001), living situation 
(X2(20)=171.88, p<.001), work situation (X2(24)=200.67, p<.001), current training 
(X2(4)=23.04, p<.001), education (X2(12)=50.37, p<.001), ethnicity (X2(20)=110.50, p<.001), 
and comorbid type of disorder (X2(12)=118.20, p<.001), were all significantly different 
between the groups (see Table 1). For instance, Body Dysmorphic Disorder patients, 
compared to other somatoform disorder groups, were younger, more single, and with more 
co-morbidity. In addition, most sick leave was found for Undifferentiated Somatoform 
Disorder and Pain Disorder (see Table 1). 
  
 
3.2 Baseline versus 6 month treatment course of  psychological symptoms (BSI, 
BAS, MADRS), physical symptoms (PSC) and functioning (SF-36) for the 
somatoform disorder groups 
 
These results are divided into three tables: table 2, table 3, and table 4. 
 
Table 2 shows the 6 months treatment course of the total group of somatoform disorders and 
the Undifferentiated somatoform disorder group.   
 
INSERT TABLE 2 HERE 
 
For the total group of somatoform disorders, there was a significant but mostly small 
reduction at 6 months for most subscales, except for the insignificant PSC Gastro-intestinal 
and Warm/cold-urogenital subscales (see Table 2). 
 
For the Undifferentiated somatoform disorder group, there was also a significant but mostly 
small reduction at 6 months for most subscales, except for the insignificant BSI Interpersonal 
sensitivity, Hostility, Phobic anxiety, and Paranoid ideation subscales; and the insignificant 
PSC Gastro-intestinal and Warm/cold-urogenital subscales (see Table 2).  
 
Table 3 shows the 6 month treatment course of the Pain disorder and Body dysmorphic 
disorder. 
 
INSERT TABLE 3 HERE 
 
For Pain disorder, there was a significant reduction at 6 months only for the BSI 
Psychoticism subscale and for the SF-36 Physical functioning, Mental Health, Vitality 
subscales (see Table 3). 
 
For Body dysmorphic disorder, most of the available scores (PSC not available) showed an 
insignificant  reduction at 6 months. Only the following scores had a significant reduction at 
6 months: the BSI Depression, Anxiety, Phobic anxiety, Psychoticism, and Total subscales; 
BAS; MADRS; and SF-36 Social functional, Mental health, Vitality subscales (see Table 3).   
 
Finally, Table 4 shows the 6 month treatment course of Hypochondriasis.  
 
INSERT TABLE 4 HERE 
 
Patients with Hypochondriasis exhibited almost no significant differences between baseline 
and 6 months. Only the PSC General/neurological subscale showed a small significant 
reduction at 6 months (see Table 4). 
 
 
3.3 Predictors for the treatment course of symptoms (BSI total) 
The course of the BSI total score was defined by the BSI total difference score (BSI total at 6 
months – BSI total at baseline). For the total group of somatoform disorders (N=435), we 
found the following (not in table): the average BSI total difference score was -0.17, with a 
standard deviation of 0.03 (minimal difference score of -2.51, maximum difference score of 
1.77).  
 
Table 5 displays the results of the hierarchical multiple linear regression analysis for the BSI 
total difference score. 
 
INSERT TABLE 5 HERE  
 
When the effects of the pretreatment outcome BSI total score and socio-demographic 
variables were statistically controlled, we found the following three significant predictors for 
the course of the BSI difference score: PSC total score, Body Dysmorphic Disorder, and 
Hypochondriasis (explained variance by predictors: .160 or 16%). None of the 
sociodemographic variables nor comorbid disorders were significant predictors.  
 
 
3.4 Predictors for the treatment course of functioning (SF-36 Physical)   
 
The course of the SF-36 Physical functioning score was examined by means of the SF-36 
Physical  difference score (SF-36 Physical at 6 months – SF-36 Physical at baseline). The 
results for the SF-36 difference score for the total group of somatoform disorders (N=435) 
were as follows (not in table): the average SF-36 difference score was -0.86, with a standard 
deviation of 0.18 (minimal difference score of -13.00, maximum difference score of 13.01).  
 
Table 6 displays the results of the hierarchical multiple linear regression analysis concerning 
the SF-36 Physical functioning difference score. 
 
INSERT TABLE 6 HERE  
 
When the effects of the pretreatment outcome SF-36 Physical functioning score and socio-
demographic variables were statistically controlled, we found only one significant predictor 
for the course of the SF-36 difference score: PSC total score (explained variance: .078 or 
7.8%). None of the sociodemographic variables, comorbid disorders, nor somatoform 
disorder groups were significant predictors. 
 
 
 
4 DISCUSSION  
 
The most common somatoform disorder in this study was Undifferentiated somatoform 
disorder, which corresponds to other studies (e.g. Arnold et al., 2007). Our results further 
showed that patients with somatoform disorders in secondary mental health care mostly 
consisted of female participants, middle aged, the majority married, reasonably educated, and 
with rather high sick leave. Most sick leave was found for Undifferentiated Somatoform 
Disorder and Pain Disorder. Compared to other somatoform disorder groups, our Body 
Dysmorphic Disorder patients were younger, more single, and had more co-morbidity. Our 
results are in line with the literature (Kuwabara et al., 2007; Leikness et al., 2008; 
Steinbrecher & Hiller, 2011; Grover et al., 2015). Most of our patients had comorbid 
disorders, especially the combination of anxiety- and mood disorders, which is also in line 
with other studies (de Waal et al., 2004; Lieb et al. 2002; Means-Christensen et al., 2008; 
Löwe et al., 2008; Hanel et al., 2009; Carlier et al., 2014; Grover et al., 2015; Jank et al., 
2017). The clinical relevance of this comorbidity is considerable as it generally reflects more 
psychosocial disability and functional impairment, elevated risk for suicidality, more drop-
out, and increased medical care utilization (Maier and Falkai, 1999; Ansseau et al., 2004; 
Barsky et al., 2005; Beesdo et al., 2010; De Reus et al, 2013; Carlier et al., 2014). 
 
On the whole, we found an unfavourable 6-month treatment course of somatoform disorders 
with a predominantly modest decline of both symptoms and functioning. To illustrate, for the 
Total group of somatoform disorders, we found the following significant results on total 
scales (baseline versus 6 months, mean): BSI total: 1.19 versus 1.02; PSC total: 48.06 versus 
43.68; BAS: 15.09 versus 12.59; MADRS: 16.60 versus 13.49; SF-36 General health/total: 
55.30 versus 50.99 (Table 2). Somatoform disorders with a rather worse treatment course 
were Body dysmorphic disorder (only a few significant reductions on some total/subscale 
scores) and Pain disorder (only a few significant reductions on some subscales but not on 
total scales). The least positive treatment results were obtained for Hypochondriasis, with 
insignificant treatment results on all total/subscale scores, except for a significant modest 
improvement on the PSC General/neurological subscale. We eventually found that in 
particular Hypochondriasis and Body Dysmorphic Disorder were significant predictors for 
the course of symptoms. Which implies that our hypothesis concerning worse treatment 
course was confirmed for Hypochondriasis but not for Pain disorder. 
 
Our modest treatment results for somatoform disorders are in line with studies in primary 
care (e.g., Steinbrecher & Hiller, 2011) and secondary care (e.g., Zonneveld et al., 2012; 
Deary et al, 2007), but in contrast with those that found somewhat better treatment results 
(e.g., Kroenke, 2007). Possible reasons for our modest treatment results are for instance: the 
limited follow-up period of 6 months, and/or the negative influence of characteristics that 
might have hampered successful treatment outcome (e.g., maladaptive personality traits, 
dysfunctional therapeutic alliance; Reuter et al., 2014).  
 
Our results further showed that few variables could predict treatment course of somatoform 
disorders: the PSC total score, Body Dysmorphic Disorder, and Hypochondriasis were 
significant predictors for the course of the symptoms, while the PSC total score was the only 
significant predictor for the course of functioning. The literature on predictive factors for the 
course of somatoform disorders in secondary mental health care is scarce, but it mostly 
confirmed our results (e.g. Voigt et al., 2013). However, it must be mentioned here that we 
could analyse only a limited set of predictors, and it is very likely that there may also be other 
relevant course predictors (e.g., negative life events, functional disability, attributional style; 
Steinbrecher & Hiller, 2011). 
 
The strength of the present study is that it is the first study to investigate the course of 
psychological- and physical symptoms as well as functioning for various somatoform 
disorders in secondary mental health care. We had a naturalistic real world patient sample 
and used both patient- and clinician-based ratings. Our study also had limitations such as the 
lack of disorder-specific instruments and no randomized control group. The observational 
nature of our data precludes conclusions regarding whether the changes found are the result 
of treatment, as these minor changes over time could well be due to regression to the mean or 
to natural fluctuations in severity over time. We had no detailed information about treatment. 
However, previous analyses regarding our ROM-procedure showed that treatment followed 
international guidelines and consisted of psychotherapy (mostly individual CBT), 
pharmacotherapy, or combined therapy (van der Lem et al., 2011; van Fenema et al., 2012ab; 
van Noorden et al., 2012). Our study was conducted using DSM-IV criteria and three DSM-
IV somatoform disorders (Conversion disorder, Somatization disorder, Somatoform disorder 
NOS) could not be analysed, due to low prevalence. Unfortunately, the follow-up of this 
study was only 6 months. A longer follow-up might have led to more improvement, due to 
longer treatment. However, this need not necessarily be the case, as Phillips et al. (2005abc) 
have found that patients with Body dysmorphic disorder who received mental health 
treatment during 1 year were not more likely to remit than those who did not received 
treatment. Finally, our participants were all treatment-seeking, preventing generalization of 
our findings to non-treatment seeking individuals. Our sample is representative for patients 
with somatoform disorders being treated in the setting of Dutch secondary mental health care. 
Consequently, we cannot generalize our results to primary or tertiary care or to patients 
outside the Netherlands. 
 
Our results indicated that most of the somatoform disorder patients had high comorbidity as 
well as high psychopathology and low functioning, which is in line with other studies 
(Claassen-van Dessel et al., 2016; Weiss et al., 2017). Further research on the course of 
symptoms is important. For instance, Houtveen et al. (2015b) found substantial fluctuations 
in bodily complaints and mood states in patients with severe chronic somatoform disorder. 
Future course studies should preferably assess larger samples, with follow-up data obtained 
prospectively, and more frequent interval ratings (Kleinstäuber et al., 2017). Finally, more 
outcome studies are needed on the long-term effectiveness of interventions for somatoform 
disorders in secondary mental health care. After all, the treatment of DSM-5 somatic 
symptoms disorders is still in its infancy (Sharma & Manjula, 2013) and chronic severe 
somatoform disorders are often treatment-resistant (Houtveen et al., 2015a). In line with our 
results, more recent treatment studies concerning somatoform disorders have stressed the 
importance of an additional treatment focus on comorbidity (Kaplan, 2014).  Examples of 
other recent treatment studies regarding somatoform disorders are: CBT enriched with 
emotion regulation strategies (Kleinstäuber et al., 2016), Group CBT (Yoshino et al., 2015), 
Mindfulness-based cognitive therapy (van Ravesteijn et al., 2014), and Intensive 
multidisciplinary treatment (Houtveen et al., 2015a).  
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Table 1: Baseline socio-demographic and clinical characteristics for the total group and the four separate somatoform disorder groups 
 
Patient                       TOTAL  
characteristics            N=435 
Undifferentiated somatoform 
disorder N=242 
Pain disorder 
N=102 
Body dysmorphic disorder  
N=51 
Hypochondriasis  
N=40 
P-value  
Age (mean, SD)         40.49 (12.13) 41.99 (12.0)a 41.23 (11.87)a 31.63 (10.16)b 38.89 (12.01) a .000 
Gender (%)     .000 
   Male                        29.4  27.1 32.3 28.4 35.9  
Married or living  
together (%) 
 
 
 
 
 
 
 
 
.000 
   Married                    53.5 53.8 54.4 31.4 69.4  
   Widow                     13.6 13.8 18.6 7.1 11.3  
   Not married             32.8  32.4 26.9 61.5 19.4  
Housing situation  
(%) 
   
 
 
 
.000 
   Living alone            22.7 23.6 21.3 32.0 12.1  
   With family             13.8 12.0 12.7 29.6 9.7  
   With partner            39.7 38.8 38.2 27.9 55.9  
Employment status  
(%) 
    .000 
   Part time work         18.3 17.3 16.0 25.4 28.2  
   Full time work         12.7 10.3 12.4 17.8 21.0  
   Unemployed            10.2   9.2 10.1 18.3 6.5  
   Sick leave                36.0 38.4 40.2 23.1 16.1  
Current education  
(%) 
    .000 
   No                             87.1  86.6 91.7 81.1 86.3  
   Yes                           12.9 13.4 8.3 18.9 13.7  
Educational status  
(%) 
    .000 
   Primary school          10.3 9.8 11.2 7.7 12.1  
   Lower education       31.8 34.5 34.9 20.1 22.6  
   Middle education      39.3 37.9 37.3 47.9 43.5  
   Higher education      18.6 17.8 16.6 24.3 21.8  
Ethnicity (%)     .000 
   Dutch                         89.2 87.8 79.6 86.4 88.7  
Comorbidity number                      
of disorders (%) 
    .000 
   0                                 17.1 21.9a, b 16.5a 8.2a, b 15.9 b  
   1                                 35.2 31.9 38.6 25.7 33.8  
   2                                 23.9 21.3 22.6 25.7 17.2  
   3                                 13.4 13.8 15.0 16.9 15.2  
   >3                               10.5 11.2 7.3 23.5 18.0  
Comorbidity type of disorders (%)     <.001 
   Anxiety                       15.8 16.4 14.0 19.1 30.3  
   Mood                           24.7 20.6 28.0 23.0 18.6  
   Anxiety+Mood            22.6  22.1 23.8 35.5 21.4  
BSI total  
(mean, SD)                 1.19 (0.75) 
 
1.05 (0.71)a 
 
1.21 (0.79)b 
 
1.45 (0.75)c 
 
1.24 (0.82)a, b, c 
 
.000 
PSC total  
(mean, SD)               48.06 (20.82)   
 
49.10 (0.81)a 
 
48.87 (1.31) a, b 
 
24.50 (8.50) a, b 
 
40.10 (2.17) b 
 
.000 
BAS  
(mean, SD)               15.09 (6.50) 
 
14.00 (0.23) a 
 
16.22 (0.32) b 
 
13.71 (0.54) a 
 
16.40 (0.62) b 
 
.000 
MADRS  
(mean, SD)                16.60 (8.47) 
 
16.43 (0.32) a, b 
 
18.53 (0.50) c 
 
18.59 (0.77) a, c 
 
13.97 (0.79) b 
 
.000 
SF-36 total  
(mean, SD)                16.06 (3.90) 
 
16.80 (0.13) a 
 
16.58 (0.20) a 
 
13.94 (0.32) b 
 
15.53 (0.34) a 
 
.000 
Note: Values in the same row with different superscript numbers are significantly different (Post-hoc comparison by Bonferroni test, P-value <0.01).  
Significant P-values (p<.01) are printed in bold. 
Patients of the somatoform disorder groups have the registered somatoform disorder and no other somatoform disorders. 
Anxiety denotes comorbid anxiety disorders, Mood denotes comorbid mood disorders, Anxiety+Mood denotes comorbid anxiety and mood disorders.   
BSI denotes the Brief Symptom Inventory, SF-36 denotes the Short-Form Health Survey 36, PSC denotes the Physical Symptom Checklist, MADRS denotes the 
Montgomery-Asberg depression Rating Scale, BAS denotes the Brief Anxiety Scale. BSI total-, PSC total-, BAS-, MADRS- and SF-36 total scores denote the 
baseline scores.   
 
  
Table 2: Six-month treatment course of total group of somatoform disorders and Undifferentiated somatoform disorder  
Patient characteristics  Total som. 
disorder B 
N=435 
Total som. 
disorders 
6m 
N=435 
t-
value 
p-
value 
Effect 
size 
(d) 
Undifferentiated 
som. disorder B 
N=242 
Undifferentiated 
som. disorder 6m 
N=242 
t-
value 
p-
value 
Effect 
size 
(d) 
BSI (mean, SD)           
   Somatization 1.14 (0.80) 0.99 (0.83) 4.200 .000 0.20 1.13 (0.77) 0.97 (0.79) 3.293 .001 .221 
   Obsessive compulsive  1.60 (0.94) 1.40 (0.94) 5.066 .000 0.24 1.54 (0.06) 1.35 (0.89) 3.808 .000 .256 
   Interpersonal sensitivity 1.30 (1.07) 1.16 (1.01) 3.234 .001 0.16 1.08 (0.97) 0.97 (0.90) 2.107 .036 .141 
   Depression 1.40 (1.06) 1.14 (0.99) 5.974 .000 0.29 1.27 (1.02) 1.01 (0.94) 4.603 .000 .309 
   Anxiety 1.33 (0.99) 1.11 (0.94) 4.193 .000 0.25 1.17 (0.95) 0.99 (0.88) 3.682 .000 .247 
   Hostility  0.79 (0.78) 0.68 (0.75) 3.343 .001 0.16 0.72 (0.74) 0.61 (0.69) 2.596 .010 .174 
   Phobic anxiety 0.97 (0.97) 0.84 (0.90) 3.599 .001 0.17 0.79 (0.91) 0.71 (0.74) 1.792 .075 .120 
   Paranoid ideation 0.98 (0.90) 0.87 (0.86) 3.019 .003 0.15 0.86 (0.86) 0.76 (0.83) 2.056 .041 .138 
   Psychoticism  1.05 (0.86) 0.84 (0.81) 6.294 .000 0.30 0.88 (0.77) 0.72 (0.74) 3.949 .000 .265 
   Total score  1.19 (0.75) 1.02 (0.75) 5.885 .000 0.28 1.07 (0.72) 0.91 (0.69) 4.392 .000 .295 
PSC (mean, SD)           
   Autonomic  8.31 (5.15) 7.23 (5.23) 4.101 .000 0.24 8.14 (5.13) 6.77 (4.97) 4.001 .000 .297 
   General/neurological 11.87 (4.47) 10.47 (5.04) 5.143 .000 0.30 12.26 (4.42) 10.78 (5.24) 4.001 .000 .297 
   Musculoskeletal/pain 11.88 (6.03) 10.91 (6.01) 3.375 .001 0.19 12.18 (6.36) 11.16 (6.12) 2.677 .008 .198 
   Gastro-intestinal 8.82 (5.85) 8.21 (6.05) 1.935 .054 0.11 8.83 (5.72) 8.07 (5.88) 1.945 .053 .144 
   Warm/cold-urogenital 5.63 (3.90) 5.28 (3.97) 1.828 .069 0.11 5.77 (4.03) 5.23 (4.10) 2.225 .027 .166 
   Total score  48.06 (20.82) 43.68 (22.48) 4.095 .000 0.24 48.73 (20.56) 43.68 (22.07) 3.660 .000 .274 
BAS (mean, SD) 15.09 (6.50) 12.59 (6.53) 6.747 .000 0.36 14.24 (6.59) 12.63 (6.60) 3.313 .002 .250 
MADRS (mean, SD) 16.60 (8.47) 13.49 (8.78) 6.658 .000 0.35 15.89 (8.48) 13.84 (8.46) 3.201 .001 .242 
SF-36 (mean, SD)           
   Physical functioning 38.62 (24.48) 33.60 (24.98) 4.928 .000 0.24 45.05 (22.53) 38.52 (24.10) 4.153 .000 .285 
   Social functioning  54.90 (26.43) 46.06 (26.70) 6.210 .000 0.30 56.78 (24.90) 47.08 (27.12) 4.991 .000 .341 
   Limitations physical  79.10 (33.03) 68.25 (28.62) 5.496 .000 0.27 87.38 (26.18) 74.42 (35.72) 4.916 .000 .336 
   Limitations emotional  65.79 (40.63) 59.05 (42.27) 2.987 .003 0.15 65.26 (42.28) 56.85 (43.00) 2.692 .008 .184 
   Mental Health  49.98 (20.73) 43.70 (20.74) 6.313 .000 0.31 45.68 (19.98) 40.21 (20.52) 4.507 .000 .308 
   Vitality  65.72 (18.19) 58.63 (19.70) 6.826 .000 0.33 67.92 (17.69) 60.16 (21.04) 5.156 .000 .352 
   Pain  50.08 (26.57) 44.68 (26.26) 4.384 .000 0.21 54.47 (24.44) 46.16 (25.32) 4.865 .000 .333 
   General Health   55.30 (19.51) 50.99 (20.22) 4.810 .000 0.24 57.80 (19.10) 52.08 (19.01) 4.739 .000 .324 
Note: som. disorder denotes somatoform disorder, B denotes the baseline, 6m denotes after 6 months. Concerns patients with both baseline and 6 months data. 
P-value denotes the paired t-test, and significant p-values (p<.01) are printed in bold. 
BSI denotes the Brief Symptom Inventory, SF-36 denotes the Short-Form Health Survey 36, PSC denotes the Physical Symptom Checklist, MADRS denotes the 
Montgomery-Asberg depression Rating Scale, BAS denotes the Brief Anxiety Scale. 
Difference scores denote the subtractions scores of the baseline level and after 6 months.   
Table 3: Six-month treatment course of Pain disorder and Body dysmorphic disorder 
Patient characteristics  Pain 
disorder B 
N=102 
Pain 
disorder 6m 
N=102 
t-
value 
p-
value 
Effect 
size (d) 
Body dysm. 
disorder B 
N=51 
Body dysm. 
disorder 6m 
N=51 
t-
value 
p-
value 
Effect 
size (d) 
BSI (mean, SD)           
  Somatization 1.16 (0.74) 1.08 (0.77) 1.081 .282 .112 0.83 (0.78) 0.64 (0.89) 1.389 .172 .205 
  Obsessive compulsive  1.70 (0.93) 1.63 (0.94) .874 .384 .090 1.84 (0.84) 1.49 (1.02) 2.392 .021 .353 
  Interpersonal sensitivity 1.36 (1.04) 1.30 (1.01) .825 .412 .085 2.24 (1.04) 1.78 (1.05) 2.699 .010 .398 
  Depression 1.42 (1.02) 1.25 (0.94) 1.688 .095 .174 2.07 (1.02) 1.54 (1.19) 3.141 .003 .463 
  Anxiety 1.30 (0.93) 1.15 (0.89) 1.726 .088 .178 1.74 (0.96) 1.27 (1.05) 2.954 .005 .436 
  Hostility  0.88 (0.80) 0.80 (0.82) 1.133 .260 .117 0.91 (0.76) 0.80 (0.80) .786 .446 .113 
  Phobic anxiety 1.00 (0.99) 0.90 (0.89) 1.415 .160 .147 1.62 (0.88) 1.13 (0.92) 3.182 .003 .469 
  Paranoid ideation 1.01 (0.86) 1.00 (0.88) .130 .897 .013 1.31 (0.86) 1.03 (0.86) 2.048 .046 .302 
  Psychoticism  1.16 (0.94) 0.91 (0.79) 3.206 .002 .331 1.55 (0.82) 1.15 (0.95) 3.558 .001 .525 
  Total score  1.24 (0.73) 1.12 (0.72) 1.800 .075 .186 1.53 (0.86) 1.18 (0.82) 3.104 .003 .458 
PSC (mean, SD)           
  Autonomic  7.94 (4.60) 7.86 (5.46) .178 .860 .021 - - - -  
  General/neurological 11.89 (4.06) 10.79 (4.87) 2.024 .047 .240 - - - -  
  Musculoskeletal/pain 12.34 (5.12) 11.73 (6.11) 1.039 .302 .123 - - - -  
  Gastro-intestinal 8.52 (5.94) 8.90 (6.54) -.657 .513 -.078 - - - -  
  Warm/cold/urogenital 5.74 (3.84) 5.30 (3.38) 1.184 .240 .142 - - - -  
  Total score  47.95 (19.99) 45.91 (23.87) 1.006 .318 .119 - - - -  
BAS (mean, SD) 16.72 (5.93) 13.02 (5.34) 4.400 0 .483 13.52 (5.73) 9.15 (5.44) 3.426 .001 .659 
MADRS (mean, SD) 19.46 (8.20) 14.45 (9.15) 4.367 0 .479 18.04 (7.63) 12.15 (8.80) 3.788 .002 .729 
SF-36 (mean, SD)           
  Physical functioning 40.68 (23.90) 35.23 (22.68) 2.818 .006 .300 15.58 (15.93) 11.05 (14.25) 1.704 .096 .260 
  Social functioning  51.70 (24.43) 46.59 (22.24) 2.055 .043 .219 63.37 (29.55) 44.48 (31.38) 4.380 .001 .531 
  Limitations physical  80.11 (20.60) 73.01 (34.79) 1.579 .118 .168 65.12 (37.85) 46.51 (43.84) 2.531 .015 .386 
  Limitations emotional  70.08 (36.11) 64.02 (39.54) 1.330 .187 1.1142 75.19 (34.96) 65.12 (44.22) 1.253 .217 .191 
  Mental Health  53.73 (17.52) 47.23 (17.49) 3.103 .003 .331 64.00 (19.85) 47.81 (24.31) 4.116 .000 .628 
  Vitality  66.36 (16.45) 60.06 (17.18) 3.201 .002 .341 65.93 (18.56) 53.49 (20.34) 3.621 .001 .552 
  Pain  57.83 (22.36) 55.56 (21.51) .851 .397 .091 17.31 (19.14) 18.35 (21.81) -.342 .734 -.052 
  General Health  55.57 (17.36) 51.31 (20.14) 2.119 .037 .226 42.91 (20.82) 37.91 (22.50)  2.035 .048 .310 
Note: B denotes the baseline, 6m denotes after 6 months. Concerns patients with both baseline and 6 months data. 
P-value denotes the paired t-test, and significant p-values (p<.01) are printed in bold. 
BSI denotes the Brief Symptom Inventory, SF-36 denotes the Short-Form Health Survey 36, PSC denotes the Physical Symptom Checklist, MADRS denotes the 
Montgomery-Asberg depression Rating Scale, BAS denotes the Brief Anxiety Scale. 
Difference scores (Diff. scores) denote the subtractions scores of the baseline level and after 6 months.   
Body dysm. disorder denotes Body Dysmorphic disorder.   
Table 4: Six-month treatment course of Hypochondriasis 
Patient characteristics  Hypochondriasis B 
N=40 
Hypochondriasis 6m 
N=40 
t-value p-value  Effect size (d) 
BSI (mean, SD)      
  Somatization 1.08 (0.87) 1.00 (0.87) .760 .425 .122 
  Obsessive compulsive  1.28 (1.04) 1.28 (1.04) 1.449 .156 .232 
  Interpersonal sensitivity 1.30 (1.14) 1.30 (1.14) -.366 .717 -.059 
  Depression 1.23 (1.12) 1.23 (1.12) .619 .539 .099 
  Anxiety 1.50 (1.09) 1.50 (1.09) .369 .714 .059 
  Hostility  0.69 (0.89) 0.69 (0.89) 1.102 .277 .176 
  Phobic anxiety 1.06 (1.16) 1.06 (1.16) .130 .897 .021 
  Paranoid ideation 0.95 (0.98) 0.95 (0.98) .782 .439 .125 
  Psychoticism  1.02 (0.89) 1.02 (0.89) .872 .388 .140 
  Total score  1.13 (0.88) 1.13 (0.88) .747 .460 .120 
PSC (mean, SD)      
  Autonomic  8.78 (5.79) 7.19 (5.17) .1662 .109 .320 
  General/neurological 10.26 (5.45) 8.00 (4.55) 3.351 .002 .645 
  Musculoskeletal/pain 9.33 (5.58) 8.30 (4.83) 1.012 .321 .195 
  Gastro-intestinal 8.37 (5.52) 5.93 (4.57) 2.539 .017 .489 
  Warm/cold/urogenital 5.11 (3.38) 5.04 (3.42) .132 .896 .025 
  Total score  43.59 (22.56) 33.93 (19.53) 2.313 .029 .445 
BAS (mean, SD) 14.79 (6.51) 13.74 (7.16) .628 .369 .108 
MADRS (mean, SD) 12.09 (7.34) 11.15 (9.51) .911 .534 .156 
SF-36 (mean, SD)      
  Physical functioning 24.74 (25.31) 25.13 (27.23) -.155 .878 -.025 
  Social functioning  42.95 (30.05) 40.06 (31.44) .552 .584 .088 
  Limitations physical  49.34 (43.30) 40.79 (42.88) 1.447 .156 .235 
  Limitations emotional  48.72 (31.78) 49.57 (43.84) -.108 .914 -.017 
  Mental Health  47.69 (22.95) 46.67 (21.57) .283 .778 .045 
  Vitality  55.00 (20.10) 50.51 (17.76) 1.440 .158 .231 
  Pain  39.03 (25.35) 34.47 (25.22) 1.422 .163 .228 
  General Health  52.18 (21.54) 52.18 (20.06) .000 1.00 .000 
 
Note: B denotes the baseline, 6m denotes after 6 months. Concerns patients with both baseline and 6 months data. 
P-value denotes the paired t-test, and significant p-values (p<.01) are printed in bold. 
BSI denotes the Brief Symptom Inventory, SF-36 denotes the Short-Form Health Survey 36, PSC denotes the Physical Symptom Checklist, MADRS denotes the 
Montgomery-Asberg depression Rating Scale, BAS denotes the Brief Anxiety Scale. 
Difference scores (Diff. scores) denote the subtractions scores of the baseline level and after 6 months.   
Table 5: Hierarchical multiple regression analysis of the BSI total difference score (course predictors for symptoms; N=435) 
 B SE Β R2 
Step 1     
Constant  -.221 .176   
Control Variables      
BSI total  -.348*** .042 -.436  
Age  .000 .003 .009  
dFemale  .008 .065 .007  
dWidow .219 .210 .133  
dUnmarried .093 .212 .072  
dWithout partner  -.001 .227 .000  
dParttime  .012 .084 .008  
dFulltime  -.100 .085 -.062  
Explained variance by 
control variables (R2) 
   .198 
Step 2     
Constant  -.162 .248   
Control Variables      
BSI total  -.654*** .060 -.818  
Age  -.003 .003 -.062  
dFemale  -.037 .063 -.031  
dWidow .234 .201 .142  
dUnmarried .106 .204 -.053  
dWithout partner  -.055 .216 -.026  
dParttime  .038 .081 .024  
dFulltime  -.091 .082 -.057  
Predictors      
dLower education -.070 .107 -.060  
dMiddle education -.127 .108 -.108  
dHigher education  -.179 .119 -.120  
dAnxiety -.017 .100 -.011  
dMood  -.102 .087 -.077  
dAnxiety + Mood .108 .111 .073  
Total diagnoses  .033 .033 .072  
PSC total  .008*** .002 .278  
BAS  -.005 .007 -.062  
SF-36 physical .002 .002 .064  
SF-36 social  .000 .001 -.009  
Note: the constant is the difference score of BSI total (subtraction of BSI total on baseline and BSI total after 6 months). 
B denotes regression coefficient, SE denotes the standard deviation.  
R2 denotes the proportion of variance.  
d (for example dFemale) denotes dummy. These variables are accounted for as dummy variables. 
dAnxiety denotes comorbid anxiety disorder, dMood denotes comorbid mood disorder, dAnxiety+Mood denotes comorbid anxiety and mood disorder. 
Total diagnoses denotes the total comorbid disorders present besides the somatoform disorder.  
*p≤.05, **p≤.01, ***p≤.001  
 
  
SF-36 General Health .000 .002 .016  
MADRS .006 .006 .093  
Undiff. somaform disorder .086 .113 .074  
Pain disorder  .166 .121 .122  
Body dysm. disorder  1.100* .508 .107  
Hypochondrias  .453*** .135 .237  
Explained variance by 
predictors (∆R2) 
   .160 
Table 6: Hierarchical multiple regression analysis of SF-36 Physical functioning difference score (course predictors for functioning; N=435)  
 B SE Β R2 
Step 1     
Constant  -1.425 1.184   
Control Variables      
SF-36 physical  -.032*** .009 -.202  
Age  .046*  .022 .141  
dFemale  .014 .474 .002  
dWidow 1.719 1.500 .158  
dUnmarried 1.057 1.058 .124  
dWithout partner  -1.535 1.614 -.109  
dParttime  -1.189 .610 -.116  
dFulltime  -1.144 .617 -.107  
Explained variance by 
control variables (R2) 
   .076 
Step 2     
Constant  1.380 1.828   
Control Variables      
SF-36 physical  -.041*** .011 -.257  
Age  .026 .024 .081  
dFemale  -.313 .482 -.039  
dWidow 1.692 1.519 .156  
dUnmarried .807 1.552 .095  
dWithout partner  -1.306 1.633 -.093  
dParttime  -1.088 .614 -.106  
dFulltime  -1.117 .623 -.105  
Predictors      
dLower education -.415 .825 -.053  
dMiddle education -1.259 .832 -.161  
dHigher education  -1.612 .897 -.165  
dAnxiety -.249 .731 -.025  
dMood  -1.099 .651 -.126  
dAnxiety + Mood -.312 .822 -.032  
Total diagnoses  -.078 .246 -.025  
PSC total  .049*** .013 .263  
BAS  -.076 .050 -.129  
MADRS .035 .042 .079  
BSI total   -.745 .421 -.137  
Note: the constant is the difference score of SF-36 Physical functioning (subtraction of SF-36 Physical on baseline and SF-36 Physical after 6 months). 
B denotes regression coefficient, SE denotes the standard deviation.  
R2 denotes the proportion of variance.  
d (for example dFemale) denotes dummy. These variables are accounted for as dummy variables. 
dAnxiety denotes comorbid anxiety disorder, dMood denotes comorbid mood disorder, dAnxiety+Mood denotes comorbid anxiety and mood disorder. 
Total diagnoses denotes the total comorbid disorders present besides the somatoform disorder.  
*p≤.05, **p≤.01, ***p≤.001  
 
Undiff. somatoform disorder -1.371 .853 -.178  
Pain disorder  -.449 .921 -.049  
Body dysm. disorder  1.162 3.810 .017  
Hypochondriasis  .186 1.023 .015  
Explained variance by 
predictors (∆R2) 
   .078 
